- Goldman Sachs has initiated coverage on Innate Pharma (IPHYF) and added the company to its buy conviction list, sending its shares up 41% to €10.8 in Paris.
- Goldman also gave Innate a price target of €18,
- Innate specializes in the development of immunotherapy drugs for the treatment of cancer and inflammatory diseases.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs